
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter F - Biologics
#### PART 601 - LICENSING
##### Subpart C - Biologics Licensing
###### ยง 601.12 Changes to an approved application.
####### Advertisements and promotional labeling.

(4)Advertisements and promotional labeling shall be submitted to the Center for Biologics Evaluation and Research or Center for Drug Evaluation and Research in accordance with the requirements set forth in ยง 314.81(b)(3)(i) of this chapter.

(5) The submission and grant of a written request for an exception or alternative under ยง 201.26 or ยง 610.68 of this chapter satisfies the requirements in paragraphs (f)(1) through (f)(2) of this section.

(6) For purposes of paragraph (f)(2) of this section, information will be considered newly acquired if it consists of data, analyses, or other information not previously submitted to the agency, which may include (but are not limited to) data derived from new clinical studies, reports of adverse events, or new analyses of previously submitted data (e.g., meta-analyses) if the studies, events or analyses reveal risks of a different type or greater severity or frequency than previously included in submissions to FDA.
